Quarterly ResultAug 4, 2026, 04:04 PM
Pacira BioSciences Q2 Revenue $192.4M (+6%); GAAP Net Income $4.7M
AI Summary
Pacira BioSciences reported solid second-quarter 2026 financial results with total revenue of $192.4 million, a 6% increase year-over-year, and GAAP net income of $4.7 million. The company completed the divestiture of its iovera business to Zimmer Biomet for up to $140 million, receiving $73.6 million upfront. Key business highlights include expanded reimbursement for EXPAREL by UnitedHealthcare and advancement of the PCRX-201 gene therapy development program. Full-year 2026 revenue guidance was updated to $735 million to $760 million, adjusted for the iovera divestiture.
Key Highlights
- Divested iovera business to Zimmer Biomet for up to $140 million, receiving $73.6 million cash upfront.
- Reported Q2 2026 total revenue of $192.4 million, a 6% increase year-over-year.
- Achieved Q2 2026 GAAP net income of $4.7 million, or $0.12 per share.
- Reported Q2 2026 non-GAAP net income of $29.5 million, or $0.73 diluted per share.
- EXPAREL net product sales reached $147.8 million, up 3% year-over-year.
- UnitedHealthcare now provides separate reimbursement for EXPAREL in outpatient settings.
- Updated full-year 2026 total revenue guidance to $735 million to $760 million, reflecting iovera divestiture.
- PCRX-201 (gene therapy for osteoarthritis) Phase 2 ASCEND study enrollment is underway.
Price Impact
More from PCRX